Nexavar

(Sorafenib)

ApprovedSmall molecule

Sorafenib is used to treat certain types of cancer, including liver cancer, kidney cancer, and thyroid cancer. It works by slowing or stopping the growth of cancer cells in the body.[2] Nexavar is currently approved and in use across 42 indications[4].[1]

Nexavar is one of 685 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Approved.

Indications

623

Total Trials

Active Trials

684

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Prostate AdenocarcinomaApproved

Thyroid NeoplasmApproved

Thrombotic DiseaseApproved

Carcinoma of Liver and Intrahepatic Biliary TractApproved

Lung CancerApproved

Nasopharyngeal NeoplasmApproved

Liver NeoplasmApproved

Esophageal CancerActive, not recruiting

Portal HypertensionApproved

Upper Aerodigestive Tract NeoplasmApproved

Prostate AdenocarcinomaApproved

Approved

Thyroid NeoplasmApproved

Approved

Thrombotic DiseaseApproved

Approved

Carcinoma of Liver and Intrahepatic Biliary TractApproved

Approved

Lung CancerApproved

Approved

Nasopharyngeal NeoplasmApproved

Approved

Liver NeoplasmApproved

Approved

Esophageal CancerPreclinical

Active, not recruiting

Portal HypertensionApproved

Approved

Upper Aerodigestive Tract NeoplasmApproved

Approved

Showing 10 of 42 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Approved

20 2

Zolymbus

AbbVie

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Acupan

YYonsei University

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Paracetamol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT04344158

Phase 1Active, not recruiting

Neuroblastoma

NCT02298348

Q3 2027

Phase 3Active, not recruiting

Acute Myeloid Leukemia

NCT01371981

Q1 2030

Phase 3Recruiting

Sorafenib

NCT07463651

Phase 2/3Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation

NCT06972641

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma27 trials

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Terminated·TTaiRx, Inc.·Phase 2·NCT03582618·12 enrolled

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01004003·125 enrolled

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Terminated·AAbbott·Phase 3·NCT01009593·1,035 enrolled

Show 24 more trials

Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)

Unknown status·UUniversity of Turin, Italy··NCT01230697·60 enrolled

Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma

Completed·UUniversity Hospital, Bordeaux··NCT02834546·143 enrolled

Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02259647·60 enrolled

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

Completed·UUniversity of Florida·Phase 4·NCT01203787·120 enrolled

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma

Completed·SSun Yat-sen University·Phase 3·NCT03164382·262 enrolled

TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT01605734·120 enrolled

Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma

Completed·SSamsung Medical Center·Phase 1·NCT01131689·20 enrolled

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated·BBeijing Shenogen Biomedical Co., Ltd·Phase 3·NCT03236649·89 enrolled

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04344158·648 enrolled

Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

Completed·MMahidol University·Phase 2·NCT00703365·45 enrolled

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

Unknown status·SSingapore General Hospital·Phase 3·NCT01135056·360 enrolled

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Completed· Bayer logo

Bayer·Phase 2·NCT00108953·96 enrolled

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Completed·YYiviva Inc.·Phase 2·NCT04000737·62 enrolled

Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)

Terminated·UUniversity of Erlangen-Nürnberg Medical School·Phase 1·NCT00823290·2 enrolled

Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Completed·UUniversity of California, San Francisco·Phase 1·NCT01008917·25 enrolled

Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT00752063·52 enrolled

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT01032850·15 enrolled

Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)

Terminated·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT00971126·3 enrolled

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04985136·1 enrolled

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting·ZZe-yang Ding, MD··NCT05713994·300 enrolled

A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

Completed· Eisai logo

Eisai··NCT04763408·335 enrolled

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01775501·40 enrolled

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Completed· Eisai logo

Eisai·Phase 1/2·NCT01271504·102 enrolled

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Terminated·KKathy Miller·Phase 1/2·NCT02575339·11 enrolled

Liver Cancer19 trials

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Completed·RRobin Kate Kelley·Phase 2·NCT03439891·16 enrolled

Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01008566·21 enrolled

Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer

Completed·—·Phase 1·NCT01042041·18 enrolled

Show 16 more trials

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Completed·MMedical University of South Carolina·Phase 2·NCT00881751·95 enrolled

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT03211416·37 enrolled

Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT00941967·78 enrolled

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Unknown status·UUniversity College, London·Phase 3·NCT01324076·412 enrolled

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

Completed·SSwiss Cancer Institute·Phase 2·NCT01005199·106 enrolled

Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00867321·24 enrolled

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·N/A·NCT02072486·30 enrolled

Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01011010·11 enrolled

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01004978·235 enrolled

Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis

Completed·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT01075555·323 enrolled

Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT00949182·20 enrolled

Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery

Terminated·—·Phase 1·NCT00873002·3 enrolled

Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Completed·—·Phase 1·NCT01666756·18 enrolled

Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT01182272·36 enrolled

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT01075113·16 enrolled

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00767468·6 enrolled

Kidney Cancer13 trials

Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

Completed·MMedical Research Council·Phase 3·NCT00492258·1,656 enrolled

Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00301847·44 enrolled

Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00126594·80 enrolled

Show 10 more trials

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01497444·24 enrolled

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01664182·41 enrolled

Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00101114·55 enrolled

Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00126659·10 enrolled

Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

Completed·—·Phase 2·NCT00866320·49 enrolled

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00098618·40 enrolled

Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00405366·30 enrolled

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00126503·73 enrolled

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00378703·361 enrolled

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT00496756·14 enrolled

Melanoma12 trials

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00110019·823 enrolled

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00119249·74 enrolled

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Completed·—·Phase 2·NCT00602576·169 enrolled

Show 9 more trials

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

Unknown status·SSan Diego Pacific Oncology & Hematology Associates·Phase 2·NCT00492505·200 enrolled

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00387751·14 enrolled

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01851408

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00281957·109 enrolled

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT00811759·58 enrolled

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00329641·25 enrolled

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00349206·69 enrolled

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

Unknown status·SSan Diego Pacific Oncology & Hematology Associates·Phase 1/2·NCT00538005·54 enrolled

Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine

Completed·UUniversity of Zurich·Phase 2·NCT00794235·12 enrolled

Breast Cancer10 trials

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

Terminated·MMayo Clinic·Phase 2·NCT00573755·4 enrolled

Sorafenib in Treating Patients With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00096434·23 enrolled

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

Unknown status·NNorthwestern University·Phase 2·NCT00499525·180 enrolled

Show 7 more trials

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00622466·20 enrolled

Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer

Completed·—·Phase 1/2·NCT00828074·46 enrolled

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00722072·12 enrolled

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00217399·35 enrolled

Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer

Unknown status·MMcGill University·Phase 1/2·NCT00764972·36 enrolled

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

Terminated·HHoosier Cancer Research Network·Phase 2·NCT00632541·18 enrolled

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Completed·RRutgers, The State University of New Jersey·Phase 1/2·NCT00634634·52 enrolled

73 more indications

Non-Small Cell Lung Cancer6 trials

Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer

Completed·NNational Cancer Centre, Singapore·Phase 1·NCT00870532·52 enrolled

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00098540·46 enrolled

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT00547443

Show 3 more trials

A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Terminated· Bayer logo

Bayer·Phase 3·NCT00558636·91 enrolled

Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

Unknown status·YYonsei University·Phase 2·NCT00801385·47 enrolled

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00454194·110 enrolled

Metastatic Colorectal Cancer6 trials

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00826540·83 enrolled

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01383343·17 enrolled

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00134069·48 enrolled

Show 3 more trials

Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer

Completed·OOttawa Hospital Research Institute·Phase 1·NCT00780169·16 enrolled

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

Completed·UUniversity of Florida·Phase 2·NCT01471353·43 enrolled

Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT01715441·173 enrolled

Soft Tissue Sarcoma5 trials

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00880542·7 enrolled

Sorafenib and Dacarbazine in Soft Tissue Sarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00837148·37 enrolled

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT00822848·18 enrolled

Show 2 more trials

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT02050919·20 enrolled

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00330421·15 enrolled

Renal Cell Carcinoma5 trials

MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

Completed·UUniversity of Chicago·Phase 3·NCT00606866·57 enrolled

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

Completed·TTechnical University of Munich·Phase 3·NCT01613846·544 enrolled

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

Unknown status·YYamagata University·Phase 3·NCT01481870·120 enrolled

Show 2 more trials

Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Terminated·AAccelerated Community Oncology Research Network·Phase 2·NCT00557830·12 enrolled

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

Completed·AAVEO Pharmaceuticals, Inc.·Phase 3·NCT01030783·517 enrolled

Acute Myeloid Leukemia5 trials

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

Completed·HHamid Sayar·Phase 1/2·NCT01534260·37 enrolled

Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

Completed·CChildren's Oncology Group··NCT01576185·10 enrolled

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01253070·54 enrolled

Show 2 more trials

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01371981·1,645 enrolled

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01159301·44 enrolled

Sorafenib4 trials

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT07463651·594 enrolled

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

Completed·XXspray Pharma AB·Phase 1·NCT05967377·15 enrolled

Sorafenib. ICORG 06-41, V4

Completed·CCancer Trials Ireland·Phase 2·NCT01158287·54 enrolled

Show 1 more trial

Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC

Unknown status·FFudan University·Phase 2·NCT01259193·50 enrolled

Multiple Myeloma3 trials

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT00474929·103 enrolled

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·MMayo Clinic·Phase 1·NCT00687674·13 enrolled

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00253578·40 enrolled

Thyroid Cancer3 trials

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00390325·21 enrolled

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00126568·20 enrolled

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00095693·25 enrolled

Pancreatic Cancer3 trials

Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Unknown status·IInstitut Paoli-Calmettes·Phase 3·NCT00541021·104 enrolled

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00095966·35 enrolled

Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00114244·52 enrolled

Prostate Cancer3 trials

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Completed·—·Phase 2·NCT00589420·18 enrolled

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00093457·28 enrolled

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Completed·UUniversity of Washington·Phase 2·NCT00466752·5 enrolled

Metastatic Solid Tumors3 trials

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00121264·54 enrolled

Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00255658·40 enrolled

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00573690·31 enrolled

Leukemia2 trials

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00665990·49 enrolled

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01445080·70 enrolled

Lymphoma2 trials

Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00131937·14 enrolled

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00278382·33 enrolled

Acute Lymphoblastic Leukemia2 trials

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00131989·48 enrolled

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02779283·7 enrolled

Metastatic Cancer2 trials

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00112671·17 enrolled

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00112905·27 enrolled

Small Cell Lung Cancer2 trials

Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT00722969·48 enrolled

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00182689·89 enrolled

Advanced Cancer2 trials

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00244972·74 enrolled

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00303797·50 enrolled

Fallopian Tube Cancer2 trials

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00522301·6 enrolled

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00096200·44 enrolled

Glioblastoma Multiforme2 trials

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00445588·56 enrolled

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00335764·92 enrolled

Patients With Advanced Solid Tumors2 trials

Sorafenib in Treating Patients With Advanced Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00436579·110 enrolled

Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

Completed·VVirginia Commonwealth University·Phase 1·NCT01450384·37 enrolled

Chemotherapy2 trials

Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy

Completed·KKindai University·Phase 1/2·NCT00933816·37 enrolled

A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Unknown status·Ee-Therapeutics PLC·Phase 1·NCT02423239·112 enrolled

Metastatic Renal Cell Cancer2 trials

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00678392·723 enrolled

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00920816·492 enrolled

Neuroendocrine Tumors1 trial

Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00605566·22 enrolled

Advanced1 trial

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Unknown status·SSun Yat-sen University·Phase 3·NCT03468231·300 enrolled

Thrombosis1 trial

A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis

Unknown status·HHuazhong University of Science and Technology·Phase 4·NCT03178656·54 enrolled

Induction Chemotherapy1 trial

Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy

Terminated·NNational Cancer Center, Korea·Phase 2·NCT01159327·13 enrolled

Maintenance Therapy1 trial

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML

Completed·NNanfang Hospital, Southern Medical University··NCT04788420·456 enrolled

Peritoneal Cancer1 trial

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00093626·73 enrolled

Advanced Stage1 trial

Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE

Terminated·EEgyptian Society of Liver Cancer·Phase 2·NCT01539018·77 enrolled

Metastasis1 trial

Sorafenib-RT Treatment for Liver Metastasis (SLIM)

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT00892424·54 enrolled

Metastatic Head and Neck Cancer1 trial

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00096512·40 enrolled

Prospective1 trial

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Unknown status·SSun Yat-sen University·Phase 2·NCT04135690·60 enrolled

Glioma1 trial

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Completed·VVirginia Commonwealth University·Phase 2·NCT01817751·47 enrolled

Recurrent Sarcoma1 trial

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00245102·147 enrolled

Rhabdomyosarcoma1 trial

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01502410·20 enrolled

Uveal Melanoma1 trial

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination

Completed·UUniversity Hospital, Caen·Phase 2·NCT02517736·32 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·RRuijin Hospital·Phase 2/3·NCT06972641·126 enrolled

Brain Metastases1 trial

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT01276210·23 enrolled

Gemcitabine1 trial

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01222676·45 enrolled

Glioblastoma1 trial

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00329719·115 enrolled

Uterine Cancer1 trial

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00238121·56 enrolled

Temozolomide1 trial

Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

Completed·—·Phase 2·NCT00597493·32 enrolled

Solid Tumors1 trial

Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT01634893·18 enrolled

Gastroesophageal Junction Cancer1 trial

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00917462·35 enrolled

Unresectable Solid Tumor1 trial

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·UUniversity Health Network, Toronto·Phase 1·NCT00126620·17 enrolled

Malignant Glioma1 trial

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00093613·47 enrolled

Metastatic Neuroendocrine Tumor1 trial

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00131911·93 enrolled

Treatment1 trial

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET

Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine··NCT06592989·20 enrolled

Intestinal Cancer1 trial

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Unknown status·SSun Yat-sen University·N/A·NCT02013089·50 enrolled

Cancer1 trial

Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 1·NCT00405210·38 enrolled

Colorectal Carcinoma1 trial

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Completed· Bayer logo

Bayer·Phase 2·NCT00865709·198 enrolled

Metastatic1 trial

Metastatic Advanced Pancreas Sorafenib

Unknown status·GGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente·Phase 2·NCT00758381·114 enrolled

Liver Transplant1 trial

Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant

Completed·UUniversity of Washington·Phase 1·NCT00844168·4 enrolled

Patients With Locally Advanced Rectal Cancer1 trial

External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00869570·54 enrolled

Chronic Lymphocytic Leukemia1 trial

Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00303966·5 enrolled

Chronic Myelogenous Leukemia1 trial

Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00217646·36 enrolled

Unresectable1 trial

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus

Unknown status·SSichuan University·Phase 1/2·NCT04069949·39 enrolled

Nasopharyngeal Carcinoma1 trial

Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Completed·SSun Yat-sen University·Phase 2·NCT00747799·54 enrolled

Cholangiocarcinoma1 trial

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00238212·50 enrolled

Randomized1 trial

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00939627·55 enrolled

Myelodysplastic Syndrome1 trial

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Completed·IIndiana University School of Medicine·Phase 1·NCT00875745·15 enrolled

Metastatic Melanoma1 trial

A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma

Completed· Bayer logo

Bayer·Phase 2·NCT00492297·83 enrolled

Carboplatin1 trial

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

Completed·—·Phase 2·NCT00647426·7 enrolled

Neuroblastoma1 trial

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

Active, not recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT02298348·18 enrolled

Circulating Tumor Cells1 trial

Circulating Tumor Cells and Tumor DNA in HCC and NET

Completed·UUniversity of Aarhus··NCT02973204·167 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

Completed·SSun Yat-sen University·N/A·NCT05121571·114 enrolled

Refractory1 trial

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Withdrawn·SSun Yat-sen University·Phase 2·NCT03722498

RCC1 trial

Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)

Terminated·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03456401·18 enrolled

First Line Therapy1 trial

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03764293·543 enrolled

Radiofrequency Ablation1 trial

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

Completed·—·Phase 2·NCT00813293·20 enrolled

Clear Cell Renal Carcinoma1 trial

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00418496·17 enrolled

Lenvatinib1 trial

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

Unknown status·—·Phase 4·NCT04127396·72 enrolled

Randomized Controlled Trial1 trial

The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Terminated·SSun Yat-sen University·Phase 2/3·NCT02220088·79 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 1, 2005

NEXAVAR

NDA NDA021923

Dec 20, 2005

NEXAVAR

NDA NDA021923

Mar 5, 2007

NEXAVAR

NDA NDA021923

Nov 16, 2007

NEXAVAR

NDA NDA021923

Nov 16, 2007

NEXAVAR

NDA NDA021923

Nov 16, 2007

NEXAVAR

NDA NDA021923

Nov 16, 2007

NEXAVAR

NDA NDA021923

Oct 26, 2010

NEXAVAR

NDA NDA021923

Oct 26, 2010

NEXAVAR

NDA NDA021923

Mar 22, 2011

NEXAVAR

NDA NDA021923

Oct 14, 2011

NEXAVAR

NDA NDA021923

Aug 24, 2012

NEXAVAR

NDA NDA021923

Jun 11, 2013

NEXAVAR

NDA NDA021923

Oct 30, 2013

NEXAVAR

NDA NDA021923

Nov 22, 2013

NEXAVAR

NDA NDA021923

Dec 2, 2014

NEXAVAR

NDA NDA021923

Dec 22, 2017

NEXAVAR

NDA NDA021923

Dec 6, 2018

NEXAVAR

NDA NDA021923

Dec 6, 2018

NEXAVAR

NDA NDA021923

Apr 2, 2020

NEXAVAR

NDA NDA021923

Jun 19, 2020

NEXAVAR

NDA NDA021923

Jul 9, 2020

NEXAVAR

NDA NDA021923

May 20, 2021

NEXAVAR

NDA NDA021923

Aug 28, 2023

NEXAVAR

NDA NDA021923

Sources

References

[1]
ClinicalTrials.gov — 623 trial records for Sorafenib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Nexavar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Sorafenib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Sorafenib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021923). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Nexavar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serine/threonine-Protein Kinase RAF Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Serine/threonine-Protein Kinase B-RAF Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bayer

Patent Landscape[6]

Patent Cliff

Dec 24, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8877933Dec 24, 2027

9737488Sep 10, 2028